ATLANTA, May 01, 2025 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (NASDAQ: STRM), a leading provider of solutions that enable healthcare providers to improve financial performance, announced that it has signed a new contract for the use of eValuator with an 1,100 bed Ohio-based health system.
Streamline Health is leading an industry movement to improve health system financial performance through pre-bill technology solutions. eValuator’s AI-enhanced pre-bill code auditing ensures that providers can accurately capture, bill and ultimately be paid for all the care they provide while avoiding denials.
“We are honored to have the opportunity to support this leading health system’s revenue cycle,” stated Ben Stilwill, Chief Executive Officer. “We look forward to providing significant financial impact on our clients’ behalf, freeing up their resources to focus on providing care to their communities.”
About Streamline Health
Streamline Health Solutions, Inc. (Nasdaq: STRM) enables healthcare organizations to proactively address revenue leakage and improve financial performance. We deliver integrated solutions, technology-enabled services and analytics that drive compliant revenue leading to improved financial performance across the enterprise. For more information, visit www.streamlinehealth.net
To Learn More
Jacob Goldberger
Vice President, Finance
303.887.9625
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$3.06 |
Daily Change: | 0.10 3.39 |
Daily Volume: | 3,186 |
Market Cap: | US$13.070M |
May 01, 2025 January 22, 2025 December 18, 2024 December 16, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load